These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 1173370)
21. [Simultaneous determination of thyreotropic hormone and long-acting thyroid stimulator in the plasma of Basedow patients]. Földes J; Gesztesi E; Takács I Orv Hetil; 1970 Dec; 111(52):3067-70. PubMed ID: 4099957 [No Abstract] [Full Text] [Related]
22. [Estimation of thyroid stimulating immunoglobulins (TSI) by the radioreceptor method]. Wasilewska A; Nauman J Endokrynol Pol; 1978; 29(5):361-70. PubMed ID: 581373 [No Abstract] [Full Text] [Related]
23. [Long-acting thyroid stimulator (LATS), thyrotropin (TSH) and the pathogenesis of hyperthyroidism]. Lamberg BA; Gordin A Nord Med; 1968 Dec; 80(49):1651-7. PubMed ID: 5757398 [No Abstract] [Full Text] [Related]
24. [Significance of the "long acting thyroid stimulator"]. Tourneur R; Letonturier P; Sénécal P Cah Med; 1974 Mar; 15(3):121-3. PubMed ID: 4479615 [No Abstract] [Full Text] [Related]
25. [Characterization of the long-acting thyroid stimulator. Considerations on preliminary results]. Tourneur R; Letonturier P; Sénécal P MMW Munch Med Wochenschr; 1974 Mar; 116(13):677-9. PubMed ID: 4212576 [No Abstract] [Full Text] [Related]
27. [LATS and Graves' disease]. Gordon A Harefuah; 1971 May; 80(10):569-70. PubMed ID: 5171988 [No Abstract] [Full Text] [Related]
28. [The effect of immunosuppressive therapy on the long acting thyroid stimulator (LATS) and the clinical picture in patients with localized myxedema and exophthalmus]. Depisch D; Höfer R; Schatz H Wien Klin Wochenschr; 1969 Jan; 81(1):8-10. PubMed ID: 5818436 [No Abstract] [Full Text] [Related]
29. Plasma LATS and thyroid antibody level, and the clinical manifestations of Graves' disease. Földes J; Takó J; Bános C; Gesztesi E; Varga I Acta Med Acad Sci Hung; 1969; 26(3):233-43. PubMed ID: 5395883 [No Abstract] [Full Text] [Related]
30. Familial incidence of long-acting thyroid stimulator (LATS) in Graves' disease. Bonnyns M; Vanhaelst L Horm Metab Res; 1972 Mar; 4(2):132. PubMed ID: 5067566 [No Abstract] [Full Text] [Related]
31. Thyroid-stimulating immunoglobulins in Graves' disease. Smith BR; Hall R Lancet; 1974 Aug; 2(7878):427-31. PubMed ID: 4137321 [No Abstract] [Full Text] [Related]
32. Mitotic index in toxic diffuse goitres. Nilsson G Ann Clin Res; 1974 Jun; 6(3):142-5. PubMed ID: 4407913 [No Abstract] [Full Text] [Related]
33. LATS protector, the human thyroid stimulator. Adams DD N Z Med J; 1975 Jan; 81(531):22-3. PubMed ID: 1055310 [No Abstract] [Full Text] [Related]
34. The immunologic basis of Graves's disease. Volpé R N Engl J Med; 1972 Aug; 287(9):463-4. PubMed ID: 5068098 [No Abstract] [Full Text] [Related]
36. [L.A.T.S. activity during hyperthyroidism. Apropos of 143 cases of Basedow's disease]. Letonturier P; Tourneur R; Sénécal P Ann Med Interne (Paris); 1974 May; 125(5):463-7. PubMed ID: 4140703 [No Abstract] [Full Text] [Related]
37. Letter: Placental transmission of L. A. T. S. protector. Dirmikis SM; Munro DS; Hiller EJ; Crawford MJ; Wynne J; Purcell M Lancet; 1974 Dec; 2(7896):1579-80. PubMed ID: 4141025 [No Abstract] [Full Text] [Related]
38. [Thyroid acropachy with an abnormally high concentration of long acting thyroid stimulator]. Momotani N; Suzuki T; Harada S; Nishikawa Y; Ito K Horumon To Rinsho; 1972 Aug; 20(8):649-53. PubMed ID: 4678862 [No Abstract] [Full Text] [Related]
40. Evolution of the concept of the pathogenesis of toxic diffuse goitre (Graves' disease) and an assessment of the long-acting thyroid stimulator (L.A.T.S.). Hassan HA J Egypt Med Assoc; 1978; 61(1-2):111-20. PubMed ID: 583050 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]